Avapro specifically targets the angiotensin II receptor type 1 (AT1), found in many tissues but primarily in the heart’s and blood vessels’ vascular smooth muscles. The inhibition of the AT1 receptor by irbesartan prevents angiotensin II from binding to it, resulting in vasodilation, reduced vasopressin secretion, and reduced aldosterone production and secretion. This series of actions leads to a decrease in blood pressure. By managing hypertension, Avapro reduces the risk of stroke, heart attack, and kidney problems, offering significant benefits for patients requiring long-term management of their blood pressure.